Shkreli will be replaced on an interim basis by Chairman Ron Tilles, Turing said Friday in a statement. “We wish to thank Martin for helping us build Turing Pharmaceuticals into the dynamic research focused company it is today, and wish him the best in his future endeavors," Tilles said.
Read Full Article »
